Lactobacillus Supplementation in Osteoarthritis
Lactobacillus supplementation is NOT recommended for osteoarthritis management based on current clinical practice guidelines, despite emerging research showing potential benefits.
Guideline-Based Recommendations
The most authoritative and recent guidelines for OA management—the 2024 EULAR recommendations 1 and the 2020 ACR/Arthritis Foundation guidelines 2—do not include probiotics or Lactobacillus supplementation among their recommended interventions. These comprehensive guidelines extensively reviewed available evidence and made explicit recommendations for numerous treatment modalities, yet probiotics were notably absent from both strong and conditional recommendations.
The established core management strategies that should be prioritized include:
- Exercise programs (strong recommendation)
- Weight loss for overweight/obese patients (strong recommendation)
- Self-management and education programs (strong recommendation)
- Topical and oral NSAIDs (strong recommendation)
- Intraarticular glucocorticoid injections (strong recommendation)
Research Evidence Context
While guidelines do not support probiotic use, emerging research shows intriguing signals:
Lactobacillus casei Shirota demonstrated the most robust clinical evidence in a large RCT of 537 knee OA patients 3, showing:
- Significant improvements in WOMAC and VAS pain scores after 6 months
- Reduced serum hs-CRP levels (inflammatory marker)
- Strong correlation between hs-CRP reduction and symptom improvement
A 2024 meta-analysis 4 found that only Lactobacillus casei Shirota showed significant benefit across multiple outcomes, while other probiotic strains did not demonstrate consistent effects. This strain-specific finding is critical—not all Lactobacillus species are equivalent.
Additional supportive evidence includes:
- A 2025 meta-analysis of 694 patients 5 showing improvements in pain, function, and inflammatory markers
- Preclinical studies demonstrating cartilage protection and pain reduction 6, 7
Clinical Decision Algorithm
For patients with knee or hip OA:
First-line approach: Implement guideline-recommended interventions (exercise, weight management, NSAIDs, self-management programs) 1, 2
If inadequate symptom control persists after optimizing standard therapies, Lactobacillus casei Shirota supplementation could be considered as an adjunctive, low-risk intervention based on research evidence 3
Do not use probiotics as monotherapy or in place of evidence-based treatments
Avoid assuming all probiotic strains are beneficial—evidence is specific to Lactobacillus casei Shirota 4
Important Caveats
- The evidence base remains limited: Only 3-5 RCTs exist, with possible risk of bias 4
- No disease-modifying effects proven: Probiotics have not been shown to alter OA progression structurally 2
- Mechanism unclear: While the "gut-joint axis" theory suggests systemic inflammation reduction via microbiome modulation 8, this remains investigational
- Guideline absence is significant: The fact that comprehensive, evidence-based guidelines from major rheumatology societies do not recommend probiotics reflects insufficient evidence for routine clinical use
Bottom Line
Prioritize guideline-recommended treatments first 1, 2. Lactobacillus supplementation lacks sufficient evidence for formal recommendation in OA management. While Lactobacillus casei Shirota shows promise as a potential adjunctive therapy for symptom management, it should not replace established interventions and requires further large-scale validation before routine clinical adoption.